• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

SPACE-H Accelerator to Explore Astronaut Disease Treatment in Space

by Syed Hamza Sohail 09/27/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–  NaNotics LLC, a biopharmaceutical company developing NaNots® – novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood – today announced that it has been selected for the inaugural SPACE-H Accelerator program – a collaboration between Starburst, NASA’s Human Research Program (NASA HRP), the Translational Research Institute for Space Health (TRISH), Methuselah Foundation, and Microsoft Federal.

–  The SPACE-H mission is “to support entrepreneurs working to advance biological and medical capabilities with the potential to minimize the health and performance risks in human spaceflight.”

NaNotics: Pioneering Soluble Target Therapies for Oncology, Inflammatory Diseases, and Space Health Challenges

NaNotics LLC, a late preclinical-stage company based in Mill Valley, CA, is developing a cutting-edge pipeline of NaNots®, targeting soluble molecules that drive a range of oncology and inflammatory diseases with significant unmet medical needs. NaNots are engineered to specifically target soluble molecules dissolved in blood, and uniquely differentiate between biochemically identical soluble and membrane-bound targets—offering superior performance over traditional antibody therapies.

NaNots present a novel therapeutic approach by adsorbing disease-driving molecules from the bloodstream. Notably, profound tumor suppression has been demonstrated by Mayo Clinic studies using NaNots in a humanized mouse model of triple-negative breast cancer, a type that typically responds poorly to conventional drugs. Additionally, NaNots have shown efficacy in extinguishing deadly cytokine storms by rapidly adsorbing inflammatory molecules responsible for these immune overreactions.

With increasing interest in long-duration space exploration, NaNots offer a potential breakthrough in addressing health challenges posed by the harsh space environment. Factors such as accelerated aging and disease emergence require innovative treatment options. NaNots are particularly well-suited for space applications due to their ease of use—they can be administered via simple injection, with depletion of disease-driving molecules confirmed using portable blood analyzers. This makes them a valuable option for programs like NASA’s Artemis, which aims to establish a permanent lunar base, and other space missions where traditional medical technologies are impractical due to size, weight, and operational complexity.

By addressing both earthbound diseases and space-specific health challenges, NaNotics is positioned to advance the next generation of autonomous healthcare solutions.

“We’re very excited to have been selected for the first cohort of the SPACE-H program,” said Lou Hawthorne, CEO of NaNotics and the inventor of NaNots®. “The SPACE-H program is run by some of the world’s top technologists; their interest in our work speaks to the advanced nature of the NaNot platform and its potential significance for maintaining health in space as well as on Earth.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |